Advertisement
Advertisement
DMAA
D
Drugs Made In America Acquisition Corp. Ordinary Shares
10.90
USDSponsored
+0.01
+0.09%
Nov 10, 09:30 UTC -5
Closed
After-Market
10.89
-0.01
-0.06%
Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) Earnings
DMAA Earnings Reports
Positive Surprise Ratio
No Data Available for DMAA
0%
Next Report
Date of Next Report
--
Estimate for Q-- -- (Revenue/ EPS)
--
/--
Implied change from Q2 26 (Revenue/ EPS)
--
/--
Implied change from Q-- -- (Revenue/ EPS)
--
/--
Drugs Made In America Acquisition Corp. Ordinary Shares earnings per share and revenue
On Aug 10, 2026, DMAA reported earnings of -- USD per share (EPS) for Q2 26, -- the estimate of -- USD, resulting in a --% surprise. Revenue reached --, compared to an expected --, with a --% difference.
Looking ahead to -- --, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Novanta Inc. Tangible Equity Units
Report Date
Nov 09, 2026 For Q3 26
Estimate
$0.98
Actual
$1.05
Surprise
+6.49%
Horizon Quantum Holdings Ltd. Class A Ordinary Shares
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.11
Actual
$0.70
Surprise
+720.53%
BTC Development Corp. Unit
Report Date
Nov 10, 2026 For Q3 26
Estimate
-Actual
$0.06
Surprise
-
Atlanticus Holdings Corporation 9.25% Senior Notes due 2029
Report Date
Nov 05, 2026 For Q3 26
Estimate
$3.04
Actual
$4.87
Surprise
+59.78%
Atlanticus Holdings Corporation 6.125% Senior Notes due 2026
Report Date
Nov 05, 2026 For Q3 26
Estimate
$3.04
Actual
$4.87
Surprise
+59.78%
Gladstone Investment Corporation 4.875% Notes due 2028
Report Date
Nov 09, 2026 For Q2 27
Estimate
$0.28
Actual
$0.18
Surprise
-37.52%
Gladstone Investment Corporation 7.875% Notes due 2030
Report Date
Nov 09, 2026 For Q2 27
Estimate
$0.28
Actual
$0.18
Surprise
-37.52%
Emera Incorporated
Report Date
Nov 06, 2026 For Q3 26
Estimate
$0.92
Actual
$0.85
Surprise
-7.81%
Brookfield Infrastructure Corporation Class A Exchangeable Subordinate Voting Shares
Report Date
Nov 06, 2026 For Q3 26
Estimate
$0.43
Actual
-$0.04
Surprise
-109.12%
WhiteHorse Finance, Inc. 7.875% Notes due 2028
Report Date
Nov 09, 2026 For Q3 26
Estimate
$0.25
Actual
$0.22
Surprise
-13.15%
FAQ
What were Drugs Made In America Acquisition Corp. Ordinary Shares's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Drugs Made In America Acquisition Corp. Ordinary Shares reported EPS of --, missing estimates by --, and revenue of --, -- -- expectations.
How did the market react to Drugs Made In America Acquisition Corp. Ordinary Shares's Q2 2026 earnings?
The stock price moved -- --, changed from -- before the earnings release to -- the day after.
When is Drugs Made In America Acquisition Corp. Ordinary Shares expected to report next?
The next earning report is scheduled for --.
What are the forecasts for Drugs Made In America Acquisition Corp. Ordinary Shares's next earnings report?
Based on --
analysts, Drugs Made In America Acquisition Corp. Ordinary Shares is expected to report EPS of -- and revenue of -- for Q-- --.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.